ClinicalTrials.gg
Drug

Danvatirsen clinical trials

Also written AZD9150 and ISIS 481464.

studies test it
12
open now
1
in phase 3
0
first study started
2012

How each study uses danvatirsen is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the danvatirsen studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Danvatirsen
4

Development codes

AZD9150
10
ISIS 481464
4
ISIS-STAT3rx
1

Studies by the year they started

12 studies that test it; most in 2018 (3)

Studies that test danvatirsen, by start year
YearStudies
20121
20131
20152
20161
20172
20183
20231
20241

By phase

A phase 1/2 study counts in both.

Phase 1
8
Phase 2
6

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 9 · Other 3

AstraZeneca (6) · M.D. Anderson Cancer Center (1) · Acerta Pharma BV (1) · Ionis Pharmaceuticals, Inc. (1) · Montefiore Medical Center (1) · Flamingo Therapeutics NV (1) · National Cancer Institute (NCI) (1)

Often tested with

Tested in the same studies.

Ceralasertib (2) · AZD4547 (1) · Adavosertib (1) · Vistusertib (1) · Olaparib (1) · Oleclumab (1) · Trastuzumab deruxtecan (1) · Cediranib (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1

Studies that test danvatirsen.

Studies

Open first, then newest update. How each study uses danvatirsen is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 12

Given beside what is tested · 3 — danvatirsen is usual care or a partner of the new treatment

Codes

What other systems call danvatirsen · ClinicalTrials.gg INT000529

  • MeSH (NLM) C000610954danvatirsenConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 31N550RD05DANVATIRSENConfirmed FDA, NLM
  • NCI Thesaurus C101368DanvatirsenOne source FDA

Also registered as danvatirsen sodium (UNII S6A2UYH57V).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.